CINECA IRIS Institutional Research Information System

COSCIA, Marta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 7.865
EU - Europa 5.732
AS - Asia 3.136
AF - Africa 169
SA - Sud America 37
OC - Oceania 32
Continente sconosciuto - Info sul continente non disponibili 28
Totale 16.999
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.772
CN - Cina 1.844
IT - Italia 1.376
IE - Irlanda 753
SE - Svezia 717
DE - Germania 658
SG - Singapore 571
UA - Ucraina 456
AT - Austria 442
FR - Francia 384
FI - Finlandia 259
KR - Corea 158
GB - Regno Unito 145
IN - India 134
VN - Vietnam 126
SN - Senegal 124
PL - Polonia 119
CA - Canada 86
JP - Giappone 71
DK - Danimarca 56
HK - Hong Kong 51
ES - Italia 49
ID - Indonesia 47
BE - Belgio 46
GR - Grecia 44
NL - Olanda 44
RU - Federazione Russa 41
BY - Bielorussia 40
CH - Svizzera 31
AU - Australia 30
EU - Europa 28
TW - Taiwan 27
IR - Iran 25
BR - Brasile 22
CZ - Repubblica Ceca 20
UZ - Uzbekistan 18
RO - Romania 17
EG - Egitto 14
TH - Thailandia 11
TR - Turchia 11
ZA - Sudafrica 11
LU - Lussemburgo 7
PH - Filippine 7
SA - Arabia Saudita 7
AR - Argentina 6
MO - Macao, regione amministrativa speciale della Cina 6
PK - Pakistan 6
HU - Ungheria 5
IL - Israele 5
MX - Messico 5
NO - Norvegia 5
PT - Portogallo 5
NG - Nigeria 4
AM - Armenia 3
CI - Costa d'Avorio 3
CL - Cile 3
DZ - Algeria 3
IQ - Iraq 3
MK - Macedonia 3
RS - Serbia 3
UY - Uruguay 3
MA - Marocco 2
MU - Mauritius 2
NZ - Nuova Zelanda 2
SK - Slovacchia (Repubblica Slovacca) 2
TG - Togo 2
TN - Tunisia 2
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
CO - Colombia 1
EC - Ecuador 1
EE - Estonia 1
GH - Ghana 1
GT - Guatemala 1
HR - Croazia 1
IM - Isola di Man 1
KH - Cambogia 1
LK - Sri Lanka 1
MD - Moldavia 1
MY - Malesia 1
PA - Panama 1
PE - Perù 1
QA - Qatar 1
Totale 16.999
Salva come PNG Salva come JPEG
Città #
Chandler 1.339
Beijing 1.081
Dublin 751
Vienna 439
Ashburn 423
Singapore 399
Ann Arbor 393
Jacksonville 331
Torino 329
Houston 323
Nyköping 300
Fairfield 297
Medford 274
Dearborn 271
Wilmington 235
Princeton 232
Villeurbanne 217
San Mateo 169
Woodbridge 143
Fremont 135
Redwood City 115
Seattle 111
Guangzhou 105
Warsaw 99
Cambridge 89
Milan 89
Turin 88
Dong Ket 83
New York 76
Boston 59
Nanjing 57
Shanghai 56
Santa Clara 52
Toronto 52
Hefei 50
Washington 49
Hangzhou 47
Jakarta 46
Centro 45
Pisa 42
Boardman 41
Norwalk 41
Munich 39
Brussels 37
Düsseldorf 37
Chengdu 35
Rome 35
Florence 34
Los Angeles 25
Nürnberg 25
San Diego 25
Seoul 25
Chennai 24
Helsinki 23
Hebei 21
Wuhan 20
Kunming 19
Taipei 19
Falls Church 18
Pune 18
Shenyang 18
Mountain View 17
San Jose 17
Hong Kong 16
Tokyo 16
Xian 16
Central District 15
Guiyang 15
Hyderabad 15
Nanchang 15
Phoenix 15
Ottawa 14
Piemonte 14
Barcelona 13
Changsha 13
Jinan 13
São Paulo 12
Zhengzhou 12
Bologna 11
Lappeenranta 11
Linden 11
Chicago 10
Columbus 10
Des Moines 10
Jaipur 10
Paris 10
Philadelphia 10
Tianjin 10
Upper Marlboro 10
Genova 9
Provo 9
Rotterdam 9
Verona 9
Changchun 8
Dallas 8
Fuzhou 8
Oerlikon 8
Raritan 8
Shaoxing 8
Sydney 8
Totale 10.523
Salva come PNG Salva come JPEG
Nome #
Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. 715
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter's syndrome: therapeutic implications. 470
Mutations in NOTCH1 PEST-domain orchestrate CCL19-driven homing of Chronic Lymphocytic Leukemia cells by modulating the tumor suppressor gene DUSP22 313
Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives 284
REGULATION OF HIF-1 alpha IN TP53 DISRUPTED CHRONIC LYMPHOCYTIC LEUKEMIA CELLS AND ITS POTENTIAL ROLE AS A THERAPEUTIC TARGET 280
IGHV unmutated CLL B cells are more prone to spontaneous apoptosis and subject to environmental prosurvival signals than mutated CLL B cells 273
Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma 195
The Defective Proliferation of Vgamma9Vdelta2 T Cells to Zoledronic Acid In Chronic Lymphocytic Leukemia (CLL) Is a Powerful Time to First Treatment (TFT) Predictor Associated with the IGHV Mutational Status. 194
Centralized Biobanking Supports Hematology Clinical Trials: the new challenge of the University of Torino 182
The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. 179
Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0) 174
SLAMF1 regulation of chemotaxis and autophagy determines CLL patient response 162
Zoledronic Acid Restores Doxorubicin Chemosensitivity and Immunogenic Cell Death in Multidrug-Resistant Human Cancer Cells 157
Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells 155
Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia 138
HIF-1α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia 137
Magic pills: new oral drugs to treat chronic lymphocytic leukemia 132
Final Report of Bendamustine and Alemtuzumab (BEN CAM) Combination in Relapsed and Refractory Chronic Lymphocytic Leukemia 130
A phase II multi-center trial of pentostatin plus cyclophosphamide with ofatumumab in older previously untreated chronic lymphocytic leukemia patients 126
The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice 123
Identification of Novel Tumor-Associated Antigens in Chronic Lymphocytic Leukemia (CLL) by Serological Proteome Analysis (SERPA) 122
AISF position paper on HCV in immunocompromised patients 121
SLAMF1/CD150 IS A SIGNALING RECEPTOR EXPRESSED BY A SUBSET OF CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS CHARACTERIZED BY A FAVORABLE PROGNOSIS 119
Zoledronic acid repolarizes tumor-associated macrophages and inhibits mammary carcinogenesis by targeting the mevalonate pathway 118
The Mevalonate Pathway and Downstream Signal Transducers As Therapeutic Targets to Overcome Multidrug Resistance in Chronic Lymphocytic Leukemia (CLL) 118
TELOMERES SHORTEN DURING CHRONIC LYMPHOCYTIC LEUKEMIA(CLL) EVOLUTION: AN ANALYSIS ON 88 CASES 118
Effective anti-tumor immunomodulatory properties of zoledronic acid 117
Immunoglobulin variable heavy-chain (Ig Vh) mutational status and tumor microenvironment interactions in B-cell chronic lymphocytic leukaemia 116
Chlorambucil plus rituximab as front-line therapy for elderly and/or unfit chronic lymphocytic leukemia patients: Correlation with biologically-based risk stratification 113
BTK and PLCG2 mutations in patients with Chronic Lymphocytic Leukemia relapsing on Ibrutinib: a European Research Initiative on CLL (ERIC) study based on real-world evidence 113
CD73-Generated Extracellular Adenosine Creates Microenvironmental Conditions Favoring Growth and Survival of Chronic Lymphocytic Leukemia Cells 111
THE PD-1/PD-L1 AXIS CONTRIBUTES TO T CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA 109
Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment 108
Phenotypic and Functional Features of V{gamma}9/V{delta}2 T Cells in Chronic Lymphocytic Leukemia Are Strongly Correlated with the Mutational Status of the Immunoglobulin Heavy Chain Variable Region (IgVH) and Metabolic Activity of the Mevalonate Pathway in Tumor Cells 106
The Mevalonate Pathway As a Metabolic Target to Circumvent Multidrug-Resistance in Chronic Lymphocytic Leukemia Cells 105
IDENTIFICATION BY SEROLOGICAL PROTEOME ANALYSIS (SERPA) OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) 105
Selinexor in Combination with Chemotherapy or Idelalisib Elicits a Synergistic Cytotoxic Effect in Primary CLL Cells, Also Overcoming Intrinsic and Stromal Cells-Mediated Fludarabine Resistance 104
THE LOCAL MICROENVIRONMENT PLAYS A DIFFERENT ROLE IN THE SURVIVAL OF TUMOR CELLS IN CHRONIC LYMPHOCYTIC LEUKEMIA WITH MUTATED AND UNMUTATED IMMUNOGLOBULIN (IG) VH GENES 101
Identification and functional characterization of tumor specific antibody responses in chronic lymphocytic leukemia 101
Progressive Telomere Shortening Is Part of the Natural History of Chronic Lymphocytic Leukemia (CLL) and Impacts Clinical Outcom 101
Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. 100
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study 100
Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy 99
Role of PD-1/PD-L1 axis in the immune paresis of bone marrow Vγ9Vδ2 T cells in multiple myeloma 99
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE TREATMENT IN CLL PATIENTS 99
IDENTIFICATION AND FUNCTIONAL CHARACTERIZATION OF ANTIBODY IMMUNE RESPONSES ELICITED BY SELF ANTIGENS IN CHRONIC LYMPHOCYTIC LEUKEMIA 99
Regulation of HIF-1α in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role as a Therapeutic Target 97
Autoimmune complications in chronic lymphocytic leukemia in the era of targeted drugs 97
PROGRESSIVE TELOMERE SHORTENING DURING THE NATURAL HISTORY OF CHRONIC LYMPHOCYTIC LEUKEMIA 96
Targeting the mevalonate pathway and downstream signaling pathways as a strategy to circumvent multidrug-resistance in CLL cells 95
Slamf-1/CD150 Is a Signaling Receptor Expressed by a Subset of Chronic Lymphocytic Leukemia Patients Characterized by a Favorable Prognosis 94
Serological Proteome Analysis (SERPA) as a tool for the identification of novel tumor antigens in chronic lymphocytic leukemia (CLL) 93
IMPACT OF THE MEVALONATE PATHWAY AND HIF/PGP AXIS IN MODULATING MULTIDRUG-RESISTANCE IN UNMUTATED CLL CELLS 93
Idelalisib nei pazienti con leucemia linfatica cronica e linfoma follicolare: esperienza monocentrica real life 93
Telomere lenght measurement in the clinically oriented research setting: a comparison between Southern blot (SB), real time quantitative PCR (RQ-PCR) and FLOW-FISH (FF) 92
Zoledronic acid restores doxorubicin chemosensitivity and immunogenic cell death in multidrug-resistant human cancer cells 92
CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death 92
Accelerated activity of the mevalonate pathway supports the immune escape and multidrug-resistance phenotype of IGHV unmutated chronic lymphocytic leukemia cells 91
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia Microenvironment 91
The metabolism of mevalonate as a signaling pathway influencing tumor-host interactions and disease progression in chronic lymphocytic leukemia (CLL) 91
Molecular prediction of durable remission after first-line fludarabinecyclophosphamide-rituximab in chronic lymphocytic leukemia 90
Immunophenotypic profile and cytogenetic aberrations detected by interphase FISH in B-CLL patients 90
IGHV Unmutated Chronic Lymphocytic Leukemia (CLL) B Cells Are More Susceptible to Spontaneous Apoptosis Than Mutated CLL B Cells and Are Subject to the Anti-Apoptotic Effect of Environmental Signals 89
Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia 89
SELINEXOR (KPT-330) IN COMBINATION WITH CHEMOTHERAPY OR IDELALISIB ELICITS A SYNERGISTIC CYTOTOXIC EFFECT IN PRIMARY CLL CELLS, ALSO OVERCOMING INTRINSIC AND STROMAL CELLS-MEDIATED FLUDARABINE RESISTANCE 89
Serological proteome analysis (SERPA) as a tool for the identification of tumor antigens capable of eliciting immune responses in chronic lymphocytic leukemia (CLL) 88
AUTOIMMUNE HAEMOLYTIC ANAEMIA DURING BENDAMUSTINE PLUS RITUXIMAB TREATMENT IN CLL PATIENTS 88
Progressive telomere shortening occurs during the natural history of chronic lymphocytic leukemia (CLL) and associates to outcome 88
Differential Effects of Microenvironmental Elements On Tumor Cells Survival in Chronic Lymphocytic Leukemia Patient Subsets with Good or Poor Prognosis 86
Expression of telomeric proteins in chronic lymphocytic leukemia (CLL) 86
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 86
Dendritic Cells Can Be Primed to Concurrently Activate Both Unconventional Gamma/delta and Conventional alpha/beta T Cells 85
SEROLOGICAL PROTEOME ANALYSIS (SERPA) FOR THE IDENTIFICATION OF TUMOR-ASSOCIATED ANTIGENS ELICITING ANTIBODY-RESPONSES IN CHRONIC LYMPHOCYTIC LEUKEMIA 85
Identification by serological proteome analysis (SERPA) of novel tumor associated antigens in chronic lymphocytic leukemia (CLL) 84
BENDAMUSTINE AND ALEMTUZUMAB (BEN CAM) COMBINATION IN RELAPSED AND REFRACTORY CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL): PHASE I SAFETY PROFILE RESULTS OF THE ITALIAN TRIAL 84
Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 84
Ibrutinib Treatment Mitigates Phenotypic Alterations of Non-Neoplastic Immune Cell Compartments in Chronic Lymphocytic Leukemia 83
B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide 83
Real life use of bendamustine in elderly patients with lymphoid neoplasia 83
Immune Modulation by Zoledronic Acid in Human Myeloma: An Advantageous Cross Talk between V{gamma}9V{delta}2 T Cells, {alpha}{beta} CD8+ T Cells, Regulatory T Cells, and Dendritic Cells 82
The PD-1/PD-L1 Axis Contributes to T Cell Dysfunction in Chronic Lymphocytic Leukemia 82
Identification by serological proteome analysis (SERPA) of tumor-associated antigens eliciting antibody-responses in chronic lymphocytic leukemia 82
IGHV1-69/D3-16/J3 SUBSET 6 IS ASSOCIATED WITH INDOLENT DISEASE COURSE OF EARLY STAGE CLL (RAI 0) INDEPENDENT OF UNMUTATED STATUS 81
CD200 INCLUDED IN A 4-MARKER MODIFIED MATUTES SCORE PROVIDES OPTIMAL SENSITIVITYAND SPECIFICITY FOR THE DIAGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA 81
null 80
Progressive telomere shortening is part of the natural history of chronic lymphocytic leukaemia and impacts clinical outcome: Evidences from long term follow-up 80
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespective of the disease status. 80
MAKING THE RIGHT CHOICE: THE ROLE OF FITNESS STATUS IN THE MANAGEMENT OF FIRST-LINE TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS (CLL FITNESS STUDY) 80
Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. 79
Bendamustine and subcutaneous Alemtuzumab combination is an effective treatment in relapsed/refractory chronic lymphocytic leukemia patients. 79
HIF-1 alpha Upregulation in TP53 Disrupted Chronic Lymphocytic Leukemia Cells and Its Potential Role As a Therapeutic Target 79
Effector gammadelta T cells and tumor cells as immune targets of zoledronic acid in multiple myeloma 78
Bendamustine and alemtuzumab (BEN CAM) combination in relapsed and refractory chronic lymphocytic leukaemia (CLL): interim report of the italian trial 77
Zoledronic acid impairs mammary carcinogenesis in BALB/c mice transgenic for the Her-2/neu oncogene. 77
Increased expression of non-functional killer inhibitory receptor CD94 in CD8+ cells of myeloma patients. 77
Comprehensive assessment of the TCRBV repertoire in small T-cell samples by means of an improved and convenient multiplex PCR method 76
Frequency and function of regulatory T cells (Tregs) are highly preserved in multiple myeloma 76
ROLE OF THE MEVALONATE PATHWAY IN THE IMMUNOMODULATORY ACTIVITY OF ZOLEDRONIC ACID 76
Outcome of Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and/or 17p Deletion/TP53 Mutations Treated with Ibrutinib According to a Named Patient Program (NPP) in Italy: Preliminary Analysis of a Real Life Retrospective Study 76
PHENOTYPIC AND FUNCTIONAL FEATURES OF VGAMMA9/VDELTA2 T CELLS CORRELATE WITH THE MUTATIONAL STATUS OF THE TUMOR IMMUNOGLOBULINE AND WITH DISEASE AGGRESSIVENESS IN CHRONIC LYMPHOCYTIC LEUKEMIA 76
Totale 11.942
Salva come PNG Salva come JPEG
Categoria #
all - tutte 54.933
article - articoli 0
book - libri 0
conference - conferenze 28.200
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 83.133
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.739 0 0 0 249 122 324 260 132 123 213 165 151
2020/20212.730 232 188 115 162 365 135 179 174 288 174 397 321
2021/20223.148 157 90 154 269 178 149 404 161 102 304 683 497
2022/20233.721 420 362 98 384 277 902 272 251 398 119 143 95
2023/20241.734 187 306 118 71 110 290 32 150 19 95 118 238
2024/2025635 40 250 192 153 0 0 0 0 0 0 0 0
Totale 17.692